tbuckley/cabot-search huggingface dataset:
Robust taxonomic classification of uncharted microbial sequences and bins with CAT and BAT
Authors: F. A. Bastiaan von Meijenfeldt, Ksenia Arkhipova, Diego D. Cambuy, Felipe H. Coutinho, Bas E. Dutilh
Journal: Genome biology (2019)

Current-day metagenomics analyses increasingly involve de novo taxonomic classification of long DNA sequences and metagenome-assembled genomes. Here, we show that the conventional best-hit approach often leads to classifications that are too specific, especially when the sequences represent novel deep lineages. We present a classification method that integrates multiple signals to classify sequences (Contig Annotation Tool, CAT) and metagenome-assembled genomes (Bin Annotation Tool, BAT). Classifications are automatically made at low taxonomic ranks if closely related organisms are present in the reference database and at higher ranks otherwise. The result is a high classification precision even for sequences from considerably unknown organisms.
P2.12-26 The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases: A Subgroup Analysis of ALTER 1202
Authors: Y. Cheng, Q. Wang, K. Li, J. Shi, B. Han, L. Wu, G. Chen, J. He, J. Wang, H. Qin, X. Li
Journal: Journal of Thoracic Oncology (2019)
The global challenge of colorectal cancer
Authors: Marianne Grønlie Guren
Journal: The Lancet. Gastroenterology & hepatology (2019)

Colorectal cancer is the third most commonly diagnosed cancer in men and the second most common cancer in women, and is also the second leading cause of cancer death worldwide.1 The incidence of colorectal cancer varies greatly across countries and by world regions, and is associated with level of socioeconomic development. Incidence is higher in regions higher on the Human Development Index (HDI), and lower in regions that are lower on the HDI.
EP1.18-07 Evaluation of Patient Outcomes Using Haematological Bio-Markers in Patients Undergoing Chemoradiation for Non Small Cell Lung Cancer
Authors: A. Horne, K. Mactier, T. Evans, H. Hayhurst, I. Phillips, A. Price, S. Campell, F. Little, A. Tufail, K. Maclennan
Journal: Journal of Thoracic Oncology (2019)
P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
Authors: H. Yu, S. Goldberg, X. Le, Z. Piotrowska, P. Smith, I. Mensi, B. Kirova, J. Chmielecki, X. Li-Sucholeicki, P. Szekeres, G. Doughton, G. Patel, P. Jewsbury, J. Riess
Journal: Journal of Thoracic Oncology (2019)
Effect of brain-derived neurotrophic factor/TrkB axis on cancer progression in colorectal cancer.
Authors: Yasuhiro Inoue, Yoshinaga Okugawa, Susumu Saigusa, Junichiro Hiro, Yuji Toiyama, Koji Tanaka, Yasuhiko Mohri, Masato Kusunoki
Journal: Journal of Clinical Oncology (2012)

e14039 Background: Brain-derived neurotrophic factor (BDNF) is one of the member of the neurotropin family known to activate the high affinity tyrosine kinase B (TrkB) receptor together with the pan-neurotropin low-affinity coreceptor p75 (p75NTR). TrkB activation by BDNF has been shown to facilitate the progression of several cancers, however, no reports have shown the clinical and biological effects of BDNF/TrkB axis expression in colorectal cancer(CRC). Methods: A total of 223 consecutive patients undergoing surgery for CRC were enrolled. We analyzed BDNF/TrkB mRNA levels by real-time reverse transcription PCR in CRC tissues, and their relationships with clinicopathological findings including survival were investigated. BDNF and TrkB expression were also evaluated by immunohistochemistry. To investigate the biological role of the BDNF/TrkB axis, recombinant human BDNF and Trk antagonist K252a were used for proliferation, migration, and anoikis assays in CRC cell lines. Results: The mean BDNF level in CRC tissue was 94.3 (0-1326.8). One hundred five of 223 patients (47.1%) showed detectable BDNF levels, whereas the remainder had no detectable. BDNF positive expression was significantly associated with undifferenciated histological type, lymph node metastasis, and hepatic metastasis. In addition, increased BDNF/TrkB axis expression associated with lymph node metastasis, hepatic metastasis, and peritoneal disseamination. Immunohistochemical analysis indicated intense BDNF expression in the cytoplasm of cancer cells, and intense TrkB expression in the nuclei of cancer cells, respectively. In vitro, administration of recombinant human BDNF promoted proliferation, anoikis resistance, and partial migration. These effects were generally inhibited by Trk antagonist K252a. Conclusions: We demonstrated the clinical and biological function of BDNF/TrkB axis in CRC. BDNF/TrkB axis appears to play an important role in cancer progression, and blocking this pathway might be clinically useful in developing therapies for patients with CRC.
MA17.11 High Sensitivity to PD-1 Blockade Therapy After Ld1 Depletion in KRAS-Driven Lung Cancer Through CD8+/CD3+ Tumor Infiltration and PD-L1 Induction
Authors: I. Baraibar, M. Román, I. López-Erdozain, A. Oliver, A. Vilalta, D. Ajona, S. Vicent, C. De Andrea, R. Pio, J.J. Lasarte, A. Calvo, I. Gil-Bazo
Journal: Journal of Thoracic Oncology (2019)
EP1.01-50 Quantitative Assessment of Subsegmental Bronchi on Thin-Section CT for Pulmonary Lymphangitis Carcinomatosa
Authors: D. Takenaka, Y. Ohno, C. Tanaka, E. Matsushiro, A. Higashida, T. Hashimoto, H. Maeda, S. Sakamoto, M. Satouchi
Journal: Journal of Thoracic Oncology (2019)
P1.12-04 A Phase I Study of the 177Lu-DOTA0-Tyr3-Octreotate in Combination with Nivolumab in Patients with Extensive-Stage Small Cell Lung Cancer
Authors: C. Kim, D. Subramaniam, S. Liu, T. Torres, G. Esposito, G. Giaccone
Journal: Journal of Thoracic Oncology (2019)
Single cell derived spheres of umbilical cord mesenchymal stem cells enhance cell stemness properties, survival ability and therapeutic potential on liver failure
Authors: Yong Qiao, Zhongjuan Xu, Yanzhen Yu, Shulan Hou, Junsa Geng, Tongqian Xiao, Yu Liang, Qun Dong, Yan Mei, Bin Wang, Hong Qiao, Jianwu Dai, Guangli Suo
Journal: Biomaterials (2019)
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
Authors: Carmine De Angelis, Chandandeep Nagi, Cliff C. Hoyt, Linying Liu, Kristin Roman, Chichung Wang, Yi Zheng, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Paolo Nuciforo, Tao Wang, Anna Tsimelzon, Sufeng Mao, Susan G. Hilsenbeck, Meghana V. Trivedi, Maria Letizia Cataldo, Anne Pavlick, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Aleix Prat, Carolina Gutierrez, Charles Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Clinical Cancer Research (2019)

Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2+ breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab treatment is unclear.Experimental Design: Hematoxylin and eosin-stained slides (n = 59) were used to score stromal (s-)TILs from pretreatment biopsies of patients enrolled in the neoadjuvant TBCRC006 trial of 12-week lapatinib plus trastuzumab therapy (plus endocrine therapy for ER+ tumors). A 60% threshold was used to define lymphocyte-predominant breast cancer (LPBC). Multiplexed immunofluorescence (m-IF) staining (CD4, CD8, CD20, CD68, and FoxP3) and multispectral imaging were performed to characterize immune infiltrates in single formalin-fixed paraffin-embedded slides (n = 33).The pathologic complete response (pCR) rate was numerically higher in patients with LPBC compared with patients with non-LPBC (50% vs. 19%, P = 0.057). Unsupervised hierarchical clustering of the five immune markers identified two patient clusters with different responses to lapatinib plus trastuzumab treatment (pCR = 7% vs. 50%, for cluster 1 vs. 2 respectively; P = 0.01). In multivariable analysis, cluster 2, characterized by high CD4+, CD8+, CD20+ s-TILs, and high CD20+ intratumoral TILs, was independently associated with a higher pCR rate (P = 0.03). Analysis of single immune subpopulations revealed a significant association of pCR with higher baseline infiltration by s-CD4, intratumoral (i-) CD4, and i-CD20+ TILs.LPBC was marginally associated with higher pCR rate than non-LPBC in patients with lapatinib plus trastuzumab treated HER2+ breast cancer. Quantitative assessment of the immune infiltrate by m-IF is feasible and may help correlate individual immune cell subpopulations and immune cell profiles with treatment response.
MA07.11 Survival Outcomes Based on Gender of Advanced Nonsmall Cell Lung Cancer Patients Treated with Pembrolizumab or Nivolumab in Everyday Clinical Practice
Authors: D. Ksienski, E. Wai, N. Croteau, A. Freeman, L. Fiorino, A. Chan, D. Fenton, G. Geller, E. Brooks, Z. Poonja, S. Irons, M. Lesperance
Journal: Journal of Thoracic Oncology (2019)
P2.17-01 Analysis of Clinical Features and Prognosis of Non-Small Cell Lung Cancer Exceeding 30 mm Depending on the Ground Glass Opacity (GGO) Ratio
Authors: A. Kagimoto, Y. Tsutani, Y. Izaki, Y. Handa, T. Mimae, Y. Miyata, M. Okada
Journal: Journal of Thoracic Oncology (2019)
P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer
Authors: M. Mino-Kenudson, M. Redman, J. Hedger, J. Daigneault, J. Botling, E. Brambilla, G. Chen, T. Chou, W. Cooper, F.R. Hirsch, D. Jain, K. Kerr, J. Longshore, F. Lopez-Rios, N. Motoi, G. Pelosi, M. Tsao, Y. Yatabe, M.B. Beasley, A. Borczuk, L. Bubendorf, J. Chung, S. Dacic, D. Hwang, Y. Minami, A. Moreira, A. Nicholson, M. Papotti, C. Poleri, N. Rekhtman, A.C. Roden, P. Russell, L. Sholl, E. Thunnissen, W. Travis, A. Yoshida, M. Wynes, I. Wistuba, S. Lantuejoul
Journal: Journal of Thoracic Oncology (2019)
P1.18-18 Feasibility of Hypofractionated Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer
Authors: N. Van Der Voort Van Zyp, M. Hashimzadah, E. Kouwenhoven, K. Maas, W. Oosterhuis, I. Walraven, J. Belderbos, M. Mast
Journal: Journal of Thoracic Oncology (2019)
P2.04-47 Tumor Mutational Load, CD8+ T Cells, Expression of PD-L1 and HLA Class I to Guide Immunotherapy Decisions
Authors: D. Hurkmans, M. Kuipers, J. Smit, R. Van Marion, R. Mathijssen, P. Postmus, P. Hiemstra, J. Aerts, J. Von Der Thüsen, S. Van Der Burg
Journal: Journal of Thoracic Oncology (2019)
Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.
Authors: Gloria Mattiuzzi, Jorge Cortes, Deborah Blamble, Elihu Estey, Hagop Kantarjian
Journal: Blood (2007)
P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC
Authors: E. Vokes, A. Adjei, M. Ahn, F. Barlesi, E. Felip, E. Garon, I. Grenga, A. Koenig, C. Martin, T. Mok, F. Mornex, N. Munshi, D. Raben, C. Robinson, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2019)
P2.11-28 Late-Breaking Abstract - Clinical Potential of Sputum Hyaluronan Measurement in the Diagnosis and Prognosis of Patients with NSCLC
Authors: J. Chinoca, H. Freitas, V. Cordeiro De Lima, M. Tariki, P. De Marchi, D. Carraro, J.R. Martins, V. De Sa
Journal: Journal of Thoracic Oncology (2019)
P1.01-19 Predictive and Prognostic Values of ctDNA Clearance in Osimertinib Treated Advanced Non-Small Cell Lung Cancer Cohort
Authors: Y. Song, S. Ma, M. Shi, X. Xu, X. Chen, Y. Wang, Z. Yang, T. Zhang, M. Li, H. Li, L. Zhang, X. Mao
Journal: Journal of Thoracic Oncology (2019)
P1.01-62 Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer
Authors: S. Mao, Y. Liu, F. Zhou, A. Xiong, B. Chen, G. Gao, J. Yu, F. Wu, Y. He, X. Chen, C. Su, S. Ren, C. Zhou
Journal: Journal of Thoracic Oncology (2019)
CD133+ Hematopoietic Cells Successfully Reconstitute Hematopoiesis Following Autologous Peripheral Blood Stem Cell Transplantation.
Authors: Gregory A. Hale, Edwin Horwitz, Wing Leung, Paul Woodard, Paul Eldridge, Usman Yusuf, Ely Benaim, Kimberly Kasow, Kumar Srivastava, Rupert Handgretinger
Journal: Blood (2004)
P1.04-83 Combining Immune Gene Polymorphism and Immune Profile Predicts Brain Metastases and Death in a Brazilian Cohort of Non-Small Cell Lung Carcinoma
Authors: J. Machado-Rugolo, A. Fabro, C. Rainho, C. Farhat, V. De Sa, A.C. Herbst, V. De Lima, E. Parra, V. Capelozzi
Journal: Journal of Thoracic Oncology (2019)
EP1.09-02 Expression of Intratumoral GFPT2 in Lung Adenocarcinoma
Authors: Y. Jin, Y. Inoue, H. Shimada, T. Hara, K. Shimaya, Y. Sakakibara, N. Inase, K. Yamanaka, O. Matsubara
Journal: Journal of Thoracic Oncology (2019)
MA17.06 Plakophilin 1 Enhances MYC Expression, Promoting Squamous Cell Lung Cancer
Authors: J. Martin-Padron, L. Boyero, M. Rodríguez, A. Andrades, I. Díaz-Cano, P. Peinado, C. Baliñas, J.C. Álvarez Pérez, I. Coira, M.E. Fárez-Vidal, P. Medina
Journal: Journal of Thoracic Oncology (2019)
P2.16-14 Survival Rates in Non-Small Cell Lung Cancer Patients in the Brazilian Private Health System: A Cohort Study
Authors: E. Cerqueira, C.G. Ferreira, R. Buzzatti Peixoto, P. Mendoça Batista, M. Datz Abadi, L. Okumura
Journal: Journal of Thoracic Oncology (2019)
Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk
Authors: Jae Jeong Yang, Danxia Yu, Yong-Bing Xiang, William Blot, Emily White, Kim Robien, Rashmi Sinha, Yikyung Park, Yumie Takata, DeAnn Lazovich, Yu-Tang Gao, Xuehong Zhang, Qing Lan, Bas Bueno-de-Mesquita, Ingegerd Johansson, Rosario Tumino, Elio Riboli, Anne Tjønneland, Guri Skeie, J. Ramón Quirós, Mattias Johansson, Stephanie A. Smith-Warner, Wei Zheng, Xiao-Ou Shu
Journal: JAMA Oncology (2019)

Dietary fiber (the main source of prebiotics) and yogurt (a probiotic food) confer various health benefits via modulating the gut microbiota and metabolic pathways. However, their associations with lung cancer risk have not been well investigated.
P2.03-01 MMP1 Secreted by Cancer Cells Induces a Pro-Tumorigenic Senescent Phenotype in Fibroblasts in Large Cell Carcinoma of the Lung
Authors: M. Gabasa, R. Ikemori, E. Radisky, N. Reguart, D. Radisky, J. Alcaraz
Journal: Journal of Thoracic Oncology (2019)
P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study
Authors: A. Tan, K.P. Chua, A. Takano, J. Alvarez, B.H. Ong, T. Koh, Z.W. Aung, A. Jain, G. Lai, W.L. Tan, M.K. Ang, Q.S. Ng, R. Kanesvaran, T. Rajasekaran, N.G. Iyer, W.T. Lim, W. Zhai, C.K. Toh, A. Skanderup, E.H. Tan, D. Tan
Journal: Journal of Thoracic Oncology (2019)
P1.17-32 The 8th Editions of the AJCC Staging System in Terms of Predicting Recurrence and Survival in Resected NSCLC Long-Term Survivors
Authors: S.H. Song, S. Lee, J.W. Suh, S.Y. Park, C.Y. Lee, D.J. Kim, H.C. Paik, K.Y. Chung, J.G. Lee
Journal: Journal of Thoracic Oncology (2019)
P2.01-59 PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
Authors: H. Itani, A. Nigi, K. Iwamoto, Y. Ito, M. Tanigawa, S. Kondo
Journal: Journal of Thoracic Oncology (2019)
EP1.01-04 Phase I/II Trial of Biweekly Nab-Paclitaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: NJLCG1402
Authors: H. Tanaka, E. Miyauchi, A. Nakamura, T. Harada, T. Nakagawa, M. Morita, D. Jingu, K. Tomoya, S. Gamou, R. Saito, A. Inoue
Journal: Journal of Thoracic Oncology (2019)
P1.01-98 Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing
Authors: H. Tran, V. Lam, M. Vasquez, L. Hong, R. Colen, N. Elshafeey, I. Hassan, V. Papadimitrakopoulou, G. Blumenschein, B. Carter, G. Simon, R. Lanman, V. Raymond, Y. Elamin, M. Altan, A. Tsao, D. Gibbons, J. Zhang, J. Heymach
Journal: Journal of Thoracic Oncology (2019)
First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation
Authors: Rizwan Romee, Sarah Cooley, Melissa Berrien-Elliott, Peter Westervelt, Michael R Verneris, John E. Wagner, Daniel J. Weisdorf, Bruce Blazar, John F DiPersio, Amanda F. Cashen, Emily K Jeng, Amy Rock, Hing C Wong, Todd A. Fehniger, Jeffrey S. Miller
Journal: Blood (2017)
George Edward Foster
Authors: Dale Vimalachandran, Linda Jane Fleming
Journal: BMJ (2019)

George Edward Foster was born in Liverpool. Encouraged to study medicine by his mother, he was awarded a scholarship to Liverpool University. He enjoyed his student days, recalling that he tried not to drink too much at least once or twice a week.

After house jobs in Liverpool, he became a demonstrator and lecturer in anatomy in the city for three years. During this time he passed part 1 of the FRCS and completed an MD in neurobiology. The latter work lead to the first of many published papers and a lifelong interest in research.

George returned to surgical training in 1972 at …
P1.17-13 Next Generation Sequencing of the Circulating Small RNA from Serum Identifies Small RNA-Based Biomarker Panel for Stage I-II Lung Adenocarcinoma
Authors: D. Ueda, Y. Tsutani, T. Mimae, Y. Miyata, M. Okada, H. Tahara
Journal: Journal of Thoracic Oncology (2019)
P2.05-08 Diagnostic Yield of EBUS-TBNA in Evaluation of PD-L1 Expression for Advanced Non-Small Cell Lung Cancer
Authors: K. Mineura, M. Hamaji, S. Tanaka, Y. Yutaka, D. Nakajima, Y. Yamada, A. Ohsumi, T. Menju, T.F. Chen-Yoshikawa, H. Date
Journal: Journal of Thoracic Oncology (2019)
P1.03-06 Integrative Omics Analysis Reveals Important Roles of Adenosine Diphosphate in Haemostasis and Platelet Activation in NSCLC
Authors: L. Hoang, C. Domingo-Sabugo, E. Starren, S. Willis-Owen, A. Nicholson, D. Morris-Rosendahl, M. Moffatt, W. Cookson
Journal: Journal of Thoracic Oncology (2019)
MA09.01 A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naïve Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: C. Kim, S. Liu, J. Crawford, D. Subramaniam, G. Giaccone
Journal: Journal of Thoracic Oncology (2019)
Association of Practitioner Interfacility Triage Performance With Outcomes for Severely Injured Patients With Fee-for-Service Medicare Insurance
Authors: Deepika Mohan, David J. Wallace, Samantha J. Kerti, Derek C. Angus, Matthew R. Rosengart, Amber E. Barnato, Donald M. Yealy, Baruch Fischhoff, Chung-Chou Chang, Jeremy M. Kahn
Journal: JAMA Surgery (2019)

Despite evidence that treatment of severely injured patients at trauma centers is associated with reduced mortality, nearly half of all such patients are treated at nontrauma centers (undertriaged). Little is known about whether interfacility undertriage occurs because of practitioner decision-making or institutional and regional factors.
P2.14-11 Retreatment with EGFR-TKI for 541 NSCLC Patients with EGFR Mutation
Authors: K. Takahashi, K. Ito, K. Murotani, K. Asada, M. Okuno, T. Kimura, A. Kubo, T. Suda, H. Taniguchi, O. Hataji, J. Shindo, E. Kunii, T. Yoshida, K. Imaizumi, T. Hida
Journal: Journal of Thoracic Oncology (2019)
Women and children living in areas of armed conflict in Africa: a geospatial analysis of mortality and orphanhood
Authors: Zachary Wagner, Sam Heft-Neal, Paul H Wise, Robert E Black, Marshall Burke, Ties Boerma, Zulfiqar A Bhutta, Eran Bendavid
Journal: The Lancet Global Health (2019)

BackgroundThe population effects of armed conflict on non-combatant vulnerable populations are incompletely understood. We aimed to study the effects of conflict on mortality among women of childbearing age (15–49 years) and on orphanhood among children younger than 15 years in Africa.MethodsWe tested the extent to which mortality among women aged 15–49 years, and orphanhood among children younger than 15 years, increased in response to nearby armed conflict in Africa. Data on location, timing, and intensity of armed conflicts were obtained from the Uppsala Conflict Data Program, and data on the location, timing, and outcomes of women and children from Demographic and Health Surveys done in 35 African countries from 1990 to 2016. Mortality among women was obtained from sibling survival data. We used cluster-area fixed-effects regression models to compare survival of women during periods of nearby conflict (within 50 km) to survival of women in the same area during times without conflict. We used similar methods to examine the extent to which children living near armed conflicts are at increased risk of becoming orphans. We examined the effects of varying conflict intensity using number of direct battle deaths and duration of consecutive conflict exposure.FindingsWe analysed data on 1 629 352 women (19 286 387 person-years), of which 103 011 (6·3%) died (534·1 deaths per 100 000 women-years), and 2 354 041 children younger than 15 years, of which 204 276 (8·7%) had lost a parent. On average, conflict within 50 km increased women's mortality by 112 deaths per 100 000 person-years (95% CI 97–128; a 21% increase above baseline), and the probability that a child has lost at least one parent by 6·0% (95% CI 3–8). This effect was driven by high-intensity conflicts: exposure to the highest (tenth) decile conflict in terms of conflict-related deaths increased the probability of female mortality by 202% (187–218) and increased the likelihood of orphanhood by 42% compared with a conflict-free period. Among the conflict-attributed deaths, 10% were due to maternal mortality.InterpretationAfrican women of childbearing age are at a substantially increased risk of death from nearby high-intensity armed conflicts. Children exposed to conflict are analogously at increased risk of becoming orphans. This work fills gaps in literature on the harmful effects of armed conflict on non-combatants and highlights the need for humanitarian interventions to protect vulnerable populations.FundingBill & Melinda Gates Foundation to the BRANCH Consortium.
MA05.05 Post-Discontinuation Treatments in IFCT-GFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma
Authors: G. Zalcman, S. Brosseau, J. Mazieres, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I. Monnet, V. Gounant, F. Rivière, R. Gervais, H. Janicot, C. Locher, A. Langlais, J. Parienti, F. Morin, A. Scherpereel
Journal: Journal of Thoracic Oncology (2019)
P2.06-19 A Meta-Analysis of Mesothelin, Osteopontin, and Fibulin-3 as Biomarkers of Malignant Pleural Mesothelioma
Authors: C. Gillezeau, M. Van Gerwen, J. Ramos, R. Flores, M. Van Gerwen, E. Taioli
Journal: Journal of Thoracic Oncology (2019)
Construction of Bi/phthalocyanine manganese nanocomposite for trimodal imaging directed photodynamic and photothermal therapy mediated by 808 nm light
Authors: Zhao Wang, Tao Jia, Qianqian Sun, Ye Kuang, Bin Liu, Mengshu Xu, Hui Zhu, Fei He, Shili Gai, Piaoping Yang
Journal: Biomaterials (2019)
Expansion of the CD4+ effector T-cell repertoire characterizes peanut-allergic patients with heightened clinical sensitivity
Authors: Bert Ruiter, Neal P. Smith, Brinda Monian, Ang A. Tu, Elizabeth Fleming, Yamini V. Virkud, Sarita U. Patil, Charles A. Whittaker, J. Christopher Love, Wayne G. Shreffler
Journal: Journal of Allergy and Clinical Immunology (2019)